RSPR Pharma AB is a privately-held clinical stage pharmaceutical company developing a novel oral antitussive treatment for patients with excessive cough. RSPR Pharma AB is developing CRD007, a safe proprietary orally available small molecule that targets mechanisms involved in cough. In a recent controlled clinical challenge study, it was found that CRD007 significantly reduced induced cough by more than 50%.
Andreas Segerros, MBA, MSc


Mobile: +45 53 50 30 38
Email Click here to contact